These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34351436)

  • 1. Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.
    Filaci G; Fenoglio D; Nolè F; Zanardi E; Tomasello L; Aglietta M; Del Conte G; Carles J; Morales-Barrera R; Guglielmini P; Scagliotti G; Signori A; Parodi A; Kalli F; Astone G; Ferrera F; Altosole T; Lamperti G; Criscuolo D; Gianese F; Boccardo F
    Cancer Immunol Immunother; 2021 Dec; 70(12):3679-3692. PubMed ID: 34351436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
    McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS
    Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.
    Fenoglio D; Traverso P; Parodi A; Tomasello L; Negrini S; Kalli F; Battaglia F; Ferrera F; Sciallero S; Murdaca G; Setti M; Sobrero A; Boccardo F; Cittadini G; Puppo F; Criscuolo D; Carmignani G; Indiveri F; Filaci G
    Cancer Immunol Immunother; 2013 Jun; 62(6):1041-52. PubMed ID: 23591981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
    Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
    Fenoglio D; Parodi A; Lavieri R; Kalli F; Ferrera F; Tagliamacco A; Guastalla A; Lamperti MG; Giacomini M; Filaci G
    Hum Vaccin Immunother; 2015; 11(4):838-50. PubMed ID: 25714118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.
    McNeel DG; Becker JT; Eickhoff JC; Johnson LE; Bradley E; Pohlkamp I; Staab MJ; Liu G; Wilding G; Olson BM
    Clin Cancer Res; 2014 Jul; 20(14):3692-704. PubMed ID: 24850844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
    Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
    J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.
    Fujita K; Nakai Y; Kawashima A; Ujike T; Nagahara A; Nakajima T; Inoue T; Lee CM; Uemura M; Miyagawa Y; Kaneda Y; Nonomura N
    Cancer Gene Ther; 2017 Jul; 24(7):277-281. PubMed ID: 28497777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
    Westdorp H; Creemers JHA; van Oort IM; Schreibelt G; Gorris MAJ; Mehra N; Simons M; de Goede AL; van Rossum MM; Croockewit AJ; Figdor CG; Witjes JA; Aarntzen EHJG; Mus RDM; Brüning M; Petry K; Gotthardt M; Barentsz JO; de Vries IJM; Gerritsen WR
    J Immunother Cancer; 2019 Nov; 7(1):302. PubMed ID: 31727154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.
    Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R
    Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.
    Reyes D; Salazar L; Espinoza E; Pereda C; Castellón E; Valdevenito R; Huidobro C; Inés Becker M; Lladser A; López MN; Salazar-Onfray F
    Br J Cancer; 2013 Sep; 109(6):1488-97. PubMed ID: 23989944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.
    Kongsted P; Borch TH; Ellebaek E; Iversen TZ; Andersen R; Met Ö; Hansen M; Lindberg H; Sengeløv L; Svane IM
    Cytotherapy; 2017 Apr; 19(4):500-513. PubMed ID: 28215654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
    Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
    Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
    Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.